• KOL
    • KOLs Community
    • Multiple
    • Multiple Endocrine
    • Bin Tean Teh
    • Bin Tean Teh

      Bin Tean Teh

      Oncology Academic Clinical Program, Duke-NUS Medical School, Singapore 169857, Singapore. | Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer ...



      KOL Resume for Bin Tean Teh


      Oncology Academic Clinical Program, Duke-NUS Medical School, Singapore 169857, Singapore.

      Division of Medical Sciences, National Cancer Centre Singapore, Singapore, Singapore


      Duke-NUS Graduate Medical School, National Cancer Centre Singapore, Singapore 169610, Singapore


      Oncology Academic Clinical Program, Duke-NUS Medical School, Singapore City, Singapore.

      Genome Institute of Singapore, Agency for Science, Technology and Research, 138672, Singapore, Singapore


      Cancer and Stem Cell BiologyDuke‐NUS Medical School Singapore


      Division of Cancer and Stem Cell Biology, Duke-National University of Singapore Medical School, Singapore, Singapore

      Van Andel Research Institute, Center for Cancer Genomics and Quantitative Biology, Grand Rapids, MI, USA.



      Bin Tean Teh: Influence Statistics

      Sample of concepts for which Bin Tean Teh is among the top experts in the world.
      Concept World rank
      vhlrelated pheochromocytoma #1
      pl1876delinf #1
      hrpt2 mutation findings #1
      predicted cytogenetic profiles #1
      scca normal urothelium #1
      nktl 3 lymphoma #1
      pgc1αtfam signaling axis #1
      tumor syndrome #1
      illness singapore setd2 #1
      igf1r aberrations fels #1
      p001 claudin4 #1
      profiles renal #1
      spontaneous pneumothorax total #1
      survival cdc73 mice #1
      fxyd3 promising biomarker #1
      major seminoma component #1
      parafibromin expression humans #1
      parathyroid tumours fihp #1
      human tumors aflatoxin #1
      dks algorithm #1
      hyperplasia histological distinction #1
      pathways eitl #1
      flcn tumor endosomes #1
      metseektm #1
      tean teh #1
      nf1 percent #1
      prn371 durable inhibition #1
      krt15 hoxb13 #1
      pathways suppressed #1
      mutation analysis hrpt2 #1
      med12 protein expression #1
      hptjt syndrome 30 #1
      518 kinases #1
      tumours 6667 #1
      human tests reproducibility #1
      neurofibroma patient #1
      pgp95 neoplasms sensitivity #1
      hdac3 transcript variants #1
      egfr flcn #1
      renal uc #1
      bcor 6667 #1
      normal urothelium scca #1
      rcc bispecific carcinoma #1
      reintroduction flcn #1
      chromosome vhlrelated pheochromocytoma #1
      rcc common type #1
      consensus mesgc classifier #1
      somatic super #1
      patients aa exposure #1
      age uterine neoplasms #1


      Prominent publications by Bin Tean Teh

      KOL-Index: 16808

      BACKGROUND: Hyperparathyroidism is a common endocrinopathy characterised by the formation of parathyroid tumours. In this study, we determine the role of the recently identified gene, HRPT2, in parathyroid tumorigenesis.

      METHODS: Mutation analysis of HRPT2 was undertaken in 60 parathyroid tumours: five HPT-JT, three FIHP, three MEN 1, one MEN 2A, 25 sporadic adenomas, 17 hyperplastic glands, two lithium associated tumours, and four sporadic carcinomas. Loss of heterozygosity at 1q24-32 ...

      Known for Parathyroid Tumours | Hrpt2 Mutation | Loss Heterozygosity | Human Pair | Sporadic Carcinomas
      KOL-Index: 15999

      Following treatment with a demethylating agent, 5 of 11 renal cell carcinoma (RCC) cell lines showed increased expression of hepatocyte growth factor (HGF) activator inhibitor type 2 (HAI-2/SPINT2/Bikunin), a Kunitz-type protease inhibitor that regulates HGF activity. As activating mutations in the MET proto-oncogene (the HGF receptor) cause familial RCC, we investigated whether HAI-2/SPINT2 might act as a RCC tumor suppressor gene. We found that transcriptional silencing of HAI-2 in RCC ...

      Known for Tumor Suppressor | Clear Cell | Hai2 Spint2 | Papillary Carcinoma | Inhibitor Type
      KOL-Index: 15204

      The mitogen-activated protein kinase (MAPK) signaling pathways play essential roles in cell proliferation and differentiation. Recent studies also show the activation of MAPK signaling pathways in tumorigenesis, metastasis, and angiogenesis of multiple human malignancies, including renal cell carcinoma (RCC). To assess the role of this pathway in regulating the proliferation and survival of RCC cells, we first examined the expression of MAPK kinase (MKK) and MAPK in clear cell RCC and ...

      Known for Mapk Kinase | Renal Cell | Signaling Pathways | Animals Antigens | Angiogenesis Vivo
      KOL-Index: 13313

      Nasopharyngeal carcinoma (NPC) has the highest metastatic potential among head and neck cancers. Distant metastasis is the major cause of treatment failure. The role of interleukin-8 (IL-8) in NPC progression remains unknown. Our multivariate survival analyses of 255 patients with NPC revealed that higher IL-8 expression in primary NPC tissue was an independent prognostic factor for overall survival, disease-free survival, and distant metastasis-free survival of the patients. In vitro ...

      Known for Nasopharyngeal Carcinoma | Migration Invasion | Npc Metastasis | Activation Akt | Cellular Growth
      KOL-Index: 12966

      AIMS: Clear cell sarcoma of the kidney (CCSK) is a rare paediatric renal malignant tumour. The majority of CCSKs have internal tandem duplications (ITDs) of the BCOR gene, whereas a minority have the YWHAE-NUTM2 gene fusion. A third 'double-negative' (DN) category comprises CCSKs with neither BCOR ITDs nor YWHAE-NUTM2 fusion. The aim of this study was to characterise 11 histologically diagnosed CCSKs immunohistochemically (with CCND1, BCOR and CCNB3 stains) and genetically.

      METHODS AND ...

      Known for Clear Cell | Bcor Gene | Internal Tandem Duplications | Kidney Ccsk | Exon 15
      KOL-Index: 12906

      The product of the von Hippel-Lindau gene (VHL) acts as the substrate-recognition component of an E3 ubiquitin ligase complex that ubiquitylates the catalytic alpha subunit of hypoxia-inducible factor (HIF) for oxygen-dependent destruction. Although emerging evidence supports the notion that deregulated accumulation of HIF upon the loss of VHL is crucial for the development of clear-cell renal cell carcinoma (CC-RCC), the molecular events downstream of HIF governing renal oncogenesis ...

      Known for Neoplastic Humans | Cadherin Expression | Loss Vhl | Cell Tumor | Transcription Factors
      KOL-Index: 12575

      Trithorax-like group complex containing KDM6A acts antagonistically to Polycomb-repressive complex 2 (PRC2) containing EZH2 in maintaining the dynamics of the repression and activation of gene expression through H3K27 methylation. In urothelial bladder carcinoma, KDM6A (a H3K27 demethylase) is frequently mutated, but its functional consequences and therapeutic targetability remain unknown. About 70% of KDM6A mutations resulted in a total loss of expression and a consequent loss of ...

      Known for Tumor Suppressor | Loss Kdm6a | Ezh2 Inhibition | Bladder Cancer | Zeste Homolog
      KOL-Index: 12510

      BACKGROUND: Relative telomere length in peripheral blood leukocytes has been evaluated as a potential biomarker for renal cell carcinoma (RCC) risk in several studies, with conflicting findings.

      OBJECTIVE: We performed an analysis of genetic variants associated with leukocyte telomere length to assess the relationship between telomere length and RCC risk using Mendelian randomization, an approach unaffected by biases from temporal variability and reverse causation that might have ...

      Known for Telomere Length | Genetic Variants | Renal Cell Carcinoma | Mendelian Randomization | Rcc Risk
      KOL-Index: 12144

      Chuvash polycythemia is an autosomal recessive form of erythrocytosis associated with a homozygous p.Arg200Trp mutation in the von Hippel-Lindau (VHL) gene. Since this discovery, additional VHL mutations have been identified in patients with congenital erythrocytosis, in a homozygous or compound-heterozygous state. VHL is a major tumor suppressor gene, mutations in which were first described in patients presenting with VHL disease, which is characterized by the development of highly ...

      Known for Lindau Disease | Mutations E1 | Vhl Exons | Congenital Erythrocytosis | Chuvash Polycythemia
      KOL-Index: 11674

      CONTEXT: Parafibromin, encoded by HRPT2, is the first marker with significant benefit in the diagnosis of parathyroid carcinoma. However, because parafibromin is only involved in up to 70% of parathyroid carcinomas and loss of parafibromin immunoreactivity may not be observed in all cases of HRPT2 mutation, a complementary marker is needed.

      OBJECTIVE: We sought to determine the efficacy of increased expression of protein gene product 9.5 (PGP9.5), encoded by ubiquitin carboxyl-terminal ...

      Known for Parathyroid Carcinoma | Parafibromin Pgp95 | Hrpt2 Mutation | Protein Gene Product | Specificity 100
      KOL-Index: 11637

      PURPOSE: Global gene expression analysis was performed on pre-treatment biopsies from patients with squamous cell carcinoma of the head and neck (SCCHN) to discover biomarkers that can predict outcome of radiation based therapy.

      METHODS: We initially evaluated RNA expression using cDNA microarray analysis of 38 patients that received radiotherapy (RT). The five strongest candidates (VEGF, BCL-2, CLAUDIN-4, YAP-1 and c-MET) were then analysed in pre-treatment biopsies in a second group of ...

      Known for Cell Carcinoma | Head Neck | Yap1 Expression | Biomarkers Radioresistance | Analysis Radiation
      KOL-Index: 11558

      Promoter region hypermethylation and transcriptional silencing is a frequent cause of tumour suppressor gene (TSG) inactivation in many human cancers. Previously, to identify candidate epigenetically inactivated TSGs in renal cell carcinoma (RCC), we monitored changes in gene expression in four RCC cell lines after treatment with the demethylating agent 5-azacytidine. This enabled us to identify HAI-2/SPINT2 as a novel epigenetically inactivated candidate RCC TSG. To identify further ...

      Known for Renal Cell Carcinoma | Rcc Cell | Suppressor Genes | Candidate Tumour | Hai2 Spint2
      KOL-Index: 11426

      OBJECTIVE: Gastric cancer (GC) is a deadly malignancy for which new therapeutic strategies are needed. Three transcription factors, KLF5, GATA4 and GATA6, have been previously reported to exhibit genomic amplification in GC. We sought to validate these findings, investigate how these factors function to promote GC, and identify potential treatment strategies for GCs harbouring these amplifications.

      DESIGN: KLF5, GATA4 and GATA6 copy number and gene expression was examined in multiple GC ...

      Known for Cancer Development | Transcription Factors | Gene Expression | Chromatin Immunoprecipitation | Gc Cell

      Key People For Multiple Endocrine

      Top KOLs in the world
      Stephen J Marx∘∘
      multiple endocrine men1 gene primary hyperparathyroidism
      Samuel A Wells
      multiple endocrine parathyroid glands carcinoembryonic antigen
      Rajesh V Thakker
      multiple endocrine neoplasia type mutational analysis
      Britt M Skogseid
      multiple endocrine men1 gene neoplasia type
      Maria Luisa Brandi
      multiple endocrine estrogen receptor postmenopausal women
      Bruce Anthony John Ponder
      breast cancer multiple endocrine neoplasia type

      Bin Tean Teh:Expert Impact

      Concepts for whichBin Tean Tehhas direct influence:Multiple endocrine,  Renal cell,  Renal cell carcinoma,  Gene expression,  Cell carcinoma,  Men1 gene,  Breast cancer,  Parathyroid carcinoma.

      Bin Tean Teh:KOL impact

      Concepts related to the work of other authors for whichfor which Bin Tean Teh has influence:Renal cell,  Gastric cancer,  Gene expression,  Multiple endocrine,  Parathyroid carcinoma,  Somatic mutations,  Tumor suppressor.



      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Oncology Academic Clinical Program, Duke-NUS Medical School, Singapore 169857, Singapore. | Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, Singapore. | Division of Medical Sciences, National Cancer Cen

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.